Manidipine Hydrochloride Pharma Grade API is a crystalline dihydropyridine calcium-channel antagonist supplied as the hydrochloride salt for formulation into immediate-release tablets, capsules, granules, and investigational injectable dosage forms. The substance is identified chemically as 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride and is registered under CAS 89226-75-5. Two physical grades are supplied: a micronized grade for dissolution-limited oral formulations and a non-micronized grade for granulated or dry-blended systems. The hydrochloride salt is specified rather than the free base because it provides a fixed counterion and more reproducible crystallinity, while the free-base form is less convenient for solid-dosage processing due to differences in ionization and dissolution behavior. Pharmacopoeial alignment should be confirmed against the current Japanese Pharmacopoeia monograph for Manidipine Hydrochloride; where a CEP or US DMF is used, the release specification may include additional residual solvent, elemental impurity, and particle-size controls that are manufacturer-specific.

How Does the Hydrochloride Salt Form Affect Solid-State Processing?

Salt formation alters the crystal lattice and the pH-dependent solubility profile. The hydrochloride counterion is associated with the piperazine nitrogen, producing a crystalline powder that is easier to filter and dry than the free base but still has low aqueous solubility at neutral pH. X-ray powder diffraction is the principal method for polymorphic identity; the diffractogram must match the designated reference pattern before release. Attenuated total reflectance Fourier-transform infrared spectroscopy and high-performance liquid chromatography retention time provide complementary identification. Differential scanning calorimetry is useful for detecting amorphous content after milling, but published thermodynamic data for every possible polymorphic and solvated form is limited. The dihydropyridine ring is sensitive to light and oxidative degradation in solution; the crystalline bulk is more stable but should still be stored in opaque, sealed containers. Final crystallization solvent and drying temperature influence residual solvent and crystal habit. Vacuum tray drying at temperatures not exceeding 60°C is common; higher temperatures may alter crystal surface charge or increase electrostatic adhesion. Milling under nitrogen is preferred because air micronisation can generate peroxide impurities and increase oxidation potential. Photostability of the API is assessed under ICH Q1B conditions using cool white and near-UV illumination.

The limits above are representative and follow common industry control frameworks for crystalline dihydropyridine APIs. Manufacturer-specific current DMF, CEP, and pharmacopoeial monograph requirements take precedence over the example values.

Particle-Size, Moisture, and Residual Solvent Specifications

Particle-size control is performed by laser diffraction under USP <429>. For a micronized grade, the example acceptance criterion is D90 ≤20 µm; for a non-micronized grade, the criterion may be D90 60–150 µm. Dry dispersion at 1.0–2.0 bar is used to break up loose agglomerates without fracturing primary particles; the dispersion pressure must be held constant during method transfer. The specific surface area by Brunauer–Emmett–Teller analysis is commonly 2–10 m²/g for micronized material, but the value is equipment- and lot-specific. Moisture is controlled by Karl Fischer titration under USP <921>, with an example limit of ≤0.5% w/w. Residual solvents are controlled under ICH Q3C; because the synthetic route may use ethanol, isopropanol, dichloromethane, or ethyl acetate, supplier-specific limits are based on maximum daily intake and analytical capability. Elemental impurities are tested by inductively coupled plasma mass spectrometry under USP <232>/<233> and are limited according to ICH Q3D. Analytical method transfer uses HPLC with UV detection; column, mobile phase, and wavelength are product-specific. The assay and related substances methods should be validated for specificity, linearity, accuracy, precision, and robustness according to ICH Q2(R1). The detection wavelength is selected from the dihydropyridine absorbance maximum in the 230–240 nm range, but method details are supplier-specific.

Direct compression of micronized manidipine hydrochloride in low-dose tablets is constrained by cohesion and wall adhesion. The API exhibits poor bulk flow; flow function coefficient measured by shear cell according to USP <1174> may fall below 4, indicating cohesive flow. A wet mass or granulated intermediate is therefore used in many tablet lines. When direct compression is attempted, a staged preblend with microcrystalline cellulose or lactose monohydrate is prepared in a 300 L bin blender at 8–12 RPM for 10–20 minutes; the target relative standard deviation for the blend is below 5.0% before compression. Colloidal silicon dioxide can be added at 0.5–1.0% w/w to improve flow, but excess glidant may reduce tablet tensile strength. Magnesium stearate lubrication at 0.5% w/w is typical; lubricant blending should be limited to 2–5 minutes to avoid delaying dissolution. Tablet hardness is adjusted to 50–100 N for standard round convex tools, depending on formulation. Content uniformity of the finished tablets is evaluated by USP <905>; the acceptance value should not exceed 15.0. Dissolution is evaluated with USP apparatus II at 37°C and 50 RPM in 900 mL of 0.1 N hydrochloric acid or a surfactant-containing medium; for a poorly soluble DHP API, the dissolution medium, sinker type, and sampling time are product-specific.

Where granulation is required, wet granulation in a high-shear granulator with impeller tip speed not exceeding 6 m/s and fluid-bed drying below 50°C inlet air temperature reduces segregation but introduces moisture and light exposure. The wet mass is screened through a 1.0–2.0 mm screen; the dried granules are milled through a 0.8–1.25 mm screen. Roller compaction is an alternative for moisture-sensitive formulations. Ribbon density is typically controlled between 1.1 g/cm³ and 1.3 g/cm³; a roll gap of 0.8–2.0 mm and roll pressure of 30–80 kN are used for early feasibility of low-dose DHP APIs. Published product-specific data for manidipine hydrochloride roller compaction is limited; therefore process parameter ranges must be confirmed by experimental design.

When the API Is Transferred to an Injectable Matrix

An injectable presentation of manidipine hydrochloride is not a simple pH-adjusted solution. The hydrochloride salt has low aqueous solubility, and the free base precipitates at physiological pH unless a co-solvent or inclusion complex is used. For injectable-grade material, endotoxin is controlled by the limulus amoebocyte lysate test under USP <85> with an example limit of ≤0.25 EU/mg, and bioburden is tested by membrane filtration under USP <61>/<62>. Bulk solution hold time should be kept short and protected from light because the dihydropyridine ring undergoes photodegradation in dilute solution. Terminal heat sterilisation may increase oxidative degradation products; a nitrogen overlay and chelating agents may be required. Sterile filtration through a 0.22 µm filter is applicable only for a true solution or a submicron dispersion that does not distort the filter integrity test. Solubility screening should include pharmaceutically accepted co-solvents such as polyethylene glycol 300, propylene glycol, and ethanol; cyclodextrin complexation is an alternative, but loading can be limited by the binding constant. Published data for a commercial manidipine hydrochloride injection is limited, so development must rely on forced degradation and photostability data under ICH Q1B rather than compendial injection monographs.

Compared with amlodipine besylate, manidipine hydrochloride has a different molecular weight, salt form, and particle-size sensitivity. Amlodipine besylate typically presents fewer content-uniformity problems at very low dose because of its formulation history and available grades; manidipine hydrochloride is not automatically interchangeable in a direct-compression formula. Nifedipine is exceptionally light-sensitive and requires stringent yellow-light handling; manidipine hydrochloride also requires protection from light, but the crystalline state is less reactive than nifedipine in solution. Cilnidipine and lercanidipine have different substitution patterns and salt characteristics; their finished-dose dissolution methods and impurity profiles are not transferable. A manufacturer should not substitute another dihydropyridine API without re-developing primary packaging, dissolution media, and stability protocols. Comparability of manidipine hydrochloride batches across sources is established by comparing XRPD patterns, particle-size distribution, impurity profiles, and dissolution performance in a representative tablet matrix; the USP apparatus II method is a starting point, but no single test is sufficient. Impurity thresholds should be assigned using ICH Q3A/Q3B at 0.10% or 0.20% depending on maximum daily dose and confirmed against the current DMF.

Stability Data Are Reported Against ICH Q1A(R2) Conditions

Bulk API stability is evaluated in long-term and accelerated protocols at 25°C/60% RH and 40°C/75% RH, with an intermediate condition of 30°C/65% RH where applicable. Photostability is assessed under ICH Q1B using cool white and near-UV light; the solid state should be spread as a thin layer to ensure full exposure. A re-test period of 24 months is commonly assigned when the data support it; open-container and high-RH stress testing show that moisture uptake above 60% RH can cause agglomeration and reduce powder flow. The product should be stored below 25°C in tightly closed containers and protected from light; oxidative degradation can be accelerated by trace metal ions, so contact with unlined steel surfaces should be avoided. The API is incompatible with strong oxidising agents and should not be processed in equipment that leaves residual peroxides from previous operations. For injectable development, forced degradation at acid, alkaline, oxidative, thermal, and photolytic conditions is used to establish the specificity of the HPLC method; mass balance should be assessed according to ICH Q1A stress testing. Supply chain documentation normally includes the certificate of analysis, material safety data sheet, and declaration of residual solvents; the open part of the active substance master file should be referenced in regulatory submissions.